

HE Muhammad Yusuf Sheikh
Minister in charge of Ministry of National Health Services, Regulations and Coordination
Government of Pakistan

5 July 2018

Decision Letter: Request for Gavi support for Measles follow-up campaign support

Your Excellency,

I am writing in relation to Pakistan's application for Measles follow-up campaign support, which was submitted to the Gavi Secretariat in September 2017.

Following the recommendations made by the Independent Review Committee (IRC) and clarifications provided by country, I am pleased to inform you that Gavi has **approved** Pakistan's Measles follow-up campaign support application, subject to several conditions and requirements as specified in the Appendices to this letter.

The Appendices include the following important information:

Appendix A: Financial and Programmatic information – Support for Measles campaign vaccines

Appendix B: Financial and Programmatic information – Support for Injection Safety Devices

Please do not hesitate to contact my colleague Dr Hamidreza Setayesh at hsetayesh@gavi.org if you have any questions or concerns.

Yours sincerely



Hind Khatib-Othman
Managing Director, Country Programmes

cc: The Minister of Finance
The EPI Manager
WHO Country Representative
UNICEF Country Representative
Regional Working Group
WHO HQ
UNICEF Programme Division
UNICEF Supply Division

**Decision Letter
Pakistan Support for Measles Follow-up Campaign**

This Decision Letter sets out the Programme Terms of a Programme.

| | | |
|---|-------------|--------------------------|
| 1. Country: Pakistan | | |
| 2. Grant number: 18-PAK-36a-X | | |
| 3. Date of Decision Letter: 05/07/2018 | | |
| 4. Date of the Partnership Framework Agreement: 19/05/2015 | | |
| 5. Programme title: Measles follow-up campaign | | |
| 6. Vaccine type: Measles vaccine | | |
| 7. Requested product presentation and formulation of vaccine: Measles, 10 doses per vial, LYOPHILISED, Follow-up campaign | | |
| 8. Programme duration¹: 2018 | | |
| 9. Programme Budget (indicative): (subject to the terms of the partnership framework agreement) | | |
| | 2018 | Total² |
| Programme Budget (US\$) | 10,739,500 | 10,739,500 |
| 10. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement) ³ | | |
| Type of supplies to be purchased with Gavi funds in each year (Campaign) | | 2018 |
| Number of vaccines doses | | 32,519,300 |
| Annual Amounts (US\$) | | 10,739,500 |
| 11. Procurement agency: UNICEF. The Country shall release its co-financing payments to UNICEF. | | |
| 12. Self-procurement: Not applicable | | |
| 13. Co-financing obligations for campaign: Reference code: 18-PAK-36a-X-C The following table summarises the co-financing payment and quantity of supply that will be procured with such funds in the relevant year. | | |
| Type of supplies to be purchased with Country funds in each year | | 2018 |
| Number of vaccine doses | | 1,711,600 |
| Value of vaccine doses (US\$) | | 523,732 |
| Total co-financing payments (US\$) (including freight) | | 565,500 |
| 14. Vaccine introduction grant (in US\$): Not applicable | | |
| 15. Operational support for campaigns: Not applicable. A separate decision letter informing the Country about Operational support costs approval will follow. | | |
| 16. Additional reporting requirements: Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future annual amounts: Not applicable | | |
| | | Due dates |
| To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received. | | 15 May |

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the amount that Gavi has approved.

| | |
|---|---|
| In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance. | To be agreed with Secretariat |
| To report on national and sub-national programmatic readiness using the WHO Readiness Assessment Tool (or equivalent) at the recommended time points | Soon after receipt of the Decision Letter, up to 1 week before the campaign, at the recommended time points of the tool |
| To submit the Supplementary Immunisation Activity (SIA) technical report for Measles or Measles-Rubella campaign | Within 3 months of end of campaign |
| To submit the Post campaign coverage survey report for Measles-Rubella campaign | As soon as available |
| 17. Financial clarifications: Not applicable. | |
| 18. Other conditions: As a condition to Gavi's support for measles and rubella, country will be required to fully self-finance with domestic resources the measles component of the first dose of measles containing vaccine (MCV1) in its national immunisation programme for 2018 and onwards. | |

Signed by,



On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
5 July 2018

Decision Letter
Pakistan - Support for Injection Safety Devices

This Decision Letter sets out the Programme Terms of a Programme.

| | | | |
|---|------------------|------------------|--------------------------|
| 1. Country: Pakistan | | | |
| 2. Grant number: 17-PAK-32a-X; 18-PAK-32a-X; | | | |
| 3. Date of Decision Letter: 05/07/2018 | | | |
| 4. Date of the Partnership Framework Agreement: 19/05/2015 | | | |
| 5. Programme title: Injection safety devices ⁴ | | | |
| 6. Programme duration⁵: 2017-2018 | | | |
| 7. Programme Budget (indicative): (subject to the terms of the partnership framework agreement) | | | |
| | 2017 | 2018 | Total⁶ |
| Programme Budget (US\$) | 1,864,000 | 3,701,000 | 5,565,000 |
| 8. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement) ⁷ | | | |
| TOTAL injection safety devices to be purchased with Gavi funds in each year | 2017 | 2018 | |
| Number of AD syringes | | 77,400,600 | |
| Number of re-constitution syringes | | 3,765,400 | |
| Number of safety boxes | | 892,900 | |
| Annual Amounts for injection safety devices for all Gavi vaccines (US\$) | 1,864,000 | 3,701,000 | |
| Injection safety devices to be purchased with Gavi funds in each year, <u>by type of support</u> | | | |
| New Vaccine Support (NVS), Inactivated Polio Vaccine, 10 doses per vial, LIQUID, Routine | | | 2018 |
| Number of AD syringes | | | 7,550,100 |
| Number of safety boxes | | | 83,075 |
| Annual Amounts for injection safety devices for Vaccine (US\$) | | | 342,000 |
| New Vaccine Support (NVS), Pneumococcal (PCV10), 2 doses per vial, LIQUID, Routine | | | 2018 |
| Number of AD syringes | | | 15,452,300 |
| Number of safety boxes | | | 170,000 |
| Annual Amounts for injection safety devices for Vaccine (US\$) | | | 700,000 |

⁴ This does not include vaccines.

⁵ This is the entire duration of the Programme.

⁶ This is the total amount endorsed by Gavi for the entire duration of the Programme.

⁷ This is the amount that Gavi has approved.

| | |
|--|------------------|
| New Vaccine Support (NVS), DTP-HepB-Hib, 1 doses per vial, LIQUID | 2018 |
| Number of AD syringes | 20,475,700 |
| Number of safety boxes | 225,250 |
| Annual Amounts for injection safety devices for Vaccine (US\$) | 927,500 |
| | |
| New Vaccine Support (NVS), Measles, 10 doses per vial, LYOPHILISED, Follow-up campaign | 2018 |
| Number of AD syringes | 33,922,500 |
| Number of re-constitution syringes | 3,765,400 |
| Number of safety boxes | 414,575 |
| Annual Amounts for injection safety devices for Vaccine (US\$) | 1,731,500 |
| | |
| 9. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF. | |
| 10. Self-procurement: Not applicable | |
| 11. Co-financing obligations: Co-financing requirements are listed in the relevant vaccine Decision Letter. | |

Signed by,



On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
5 July 2018